Skip to main content
Terug
RADLY logo

Raia Drogasil S.A.

Datakwaliteit: 100%
RADLY
OTC Healthcare Medical - Pharmaceuticals
€ 4,54
▲ € 0,05 (1,11%)
Marktkapitalisatie: 7,93B
Dagbereik
€ 4,46 € 4,54
52-Weeksbereik
€ 2,21 € 5,34
Volume
800
50D / 200D Gem.
€ 4,77 / € 3,81
Vorige Slotkoers
€ 4,49

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (626 peers)

Metriek Aandeel Sector Mediaan
P/E 6,2 0,4
P/B 1,1 2,9
ROE % 18,5 3,8
Net Margin % 2,9 3,9
Rev Growth 5Y % 15,8 10,0
D/E 1,2 0,2

Belangrijkste Punten

Revenue grew 15,80% annually over 5 years — strong growth
ROE of 18,50% — decent returns on equity
Generating 1,01B in free cash flow
P/E of 6,24 — trading at a low valuation
Revenue growth is decelerating — 1Y growth trails 5Y average by 4,18%
Capital efficient — spends only 3,17% of revenue on capex

Groei

Revenue Growth (5Y)
15,80%
Revenue (1Y)11,62%
Earnings (1Y)6,15%
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
18,50%
ROIC12,01%
Net Margin2,93%
Op. Margin5,96%

Veiligheid

Debt / Equity
1,21
Current Ratio1,46
Interest Coverage2,46

Waardering

P/E Ratio
6,24
P/B Ratio1,08
EV/EBITDA6,29
Dividend Yield0,02%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 11,62% Revenue Growth (3Y) 13,00%
Earnings Growth (1Y) 6,15% Earnings Growth (3Y) 9,78%
Revenue Growth (5Y) 15,80% Earnings Growth (5Y) 14,03%
Profitability
Revenue (TTM) 43,38B Net Income (TTM) 1,27B
ROE 18,50% ROA 4,99%
Gross Margin 24,75% Operating Margin 5,96%
Net Margin 2,93% Free Cash Flow (TTM) 1,01B
ROIC 12,01% FCF Growth (3Y) N/A
Safety
Debt / Equity 1,21 Current Ratio 1,46
Interest Coverage 2,46 Dividend Yield 0,02%
Valuation
P/E Ratio 6,24 P/B Ratio 1,08
P/S Ratio 0,18 PEG Ratio 6,02
EV/EBITDA 6,29 Dividend Yield 0,02%
Market Cap 7,93B Enterprise Value 16,25B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 43,38B 38,86B 33,97B 29,07B 24,13B
Net Income 1,27B 1,20B 1,05B 996,11M 751,93M
EPS (Diluted) 0,77 0,72 0,62 0,58 0,44
Gross Profit 10,74B 11,55B 10,21B 8,81B 7,21B
Operating Income 2,59B 2,37B 2,08B 1,48B 1,22B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 25,46B 22,14B 20,09B 17,19B 14,78B
Total Liabilities 18,13B 15,70B 14,07B 11,78B 10,06B
Shareholders' Equity 7,32B 6,43B 5,96B 5,34B 4,68B
Total Debt 8,83B 7,70B 7,07B 6,06B 5,18B
Cash & Equivalents 509,36M 528,00M 412,32M 433,54M 356,12M
Current Assets 14,90B 12,70B 11,56B 9,58B 7,72B
Current Liabilities 10,19B 9,22B 8,08B 6,37B 5,90B

Strategiescores

This stock passed the criteria for 2 strategies

Score = fit strength (0–100)
Rank = position among all matches
Growth Price/Sales Ratio Focus (Ken Fisher)
#403 of 616
25
Custom Contrarian Investing (David Dreman)
#121 of 658
52

Recente Activiteit

Ingestapt Price/Sales Ratio Focus (Ken Fisher)
Mar 24, 2026
Ingestapt Contrarian Investing (David Dreman)
Mar 24, 2026